Clinical trials: Ticagrelor
Individualized and Combined Effects of Smoking and Diabetes on the Antiplatelet Activity in Patients Undergoing Primary Percutaneous Coronary Intervention
Individualized and Combined Effects of Diabetes and Smoking on the Antiplatelet Activity of Ticagrelor in Acute Myocardial Infarction Patients Undergoing Primary PCI
Background:Diabetes and smoking are common factors found to increase platelet reactivity in patients undergoing primary PCI. Objective: Compare the individualized and combined effects of smoking and diabetes on the antiplatelet…
- Trial name
- NCT05911659
- Testing
- Ticagrelor
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Mina Wageh Mohareb
Bleeding ,Arrhythmias, Heart Failure, Acute Renal Failure, Acute Liver Failure, Dyspnoea, Gout
Extended Drug Utilization Study Among Patients Exposed to Ticagrelor, Clopidogrel and Prasugrel
The purpose of the study is to describe patient characteristics and drug usage among patients that are prescribed ticagrelor for the first time and to compare them with patients who are prescribed clopidogrel and prasugrel for…
- Trial name
- NCT01276275
- Testing
- Risk of selected safety events
- Where
- Sweden
- Volunteers
- 7,200 people
- Sponsor
- AstraZeneca
Acute Coronary Syndrome
Ticagrelor in Fuwai Hospital
This is a single-arm non-interventional cohort study. This study is to describe the contemporary use of ticagrelor in a "real-world" setting, to reflect its acceptance and patients' compliance, and to observe its one-year safety…
- Trial name
- TIFU (NCT02765711)
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Healthy Volunteers
A Study of the Effect of Epinephrine on Platelet Reactivity in Subjects Treated With Ticagrelor
The study is an experimental observational study in ten healthy volunteers. Based on an in vitro study, it is hypothesize that a low dose epinephrine infusion will improve platelet function in healthy volunteers who have received…
- Trial name
- NCT03441412
- Testing
- Ticagrelor 90mg, Epinephrine, Metoprolol
- Where
- Sweden
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Vastra Gotaland Region
Acute Coronary Syndrome Patients With Diabetes After PCI
A sTudy of Low Dose vs Standard Dose of tIcaGrelor on Platelet Function After intErvention for Acute Coronary syndRome in Diabetes Mellitus Patients
In this study, the investigates try to confirm the hypothesis that low dose ticagrelor(60mg) had similar anti-platelets function compared with the standard dose ticagrelor in acute coronary syndrome patients with diabetes.
- Trial name
- TIGER-diabetes (NCT04307511)
- Testing
- Ticagrelor, Aspirin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Tong Ren Hospital
Acute Coronary Syndrome, Ischemic Stroke
Study to Assess Pharmacokinetics, Pharmacodynamics and Safety of Tiprogrel in Healthy Subjects
This study is designed to evaluate the pharmacokinetics, pharmacodynamics and safety in healthy subjects with multiple administration of Tiprogrel.
- Trial name
- NCT06584812
- Testing
- Tiprogrel, Clopidogrel, Ticagrelor
- Where
- China
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Tianjin Institute of Pharmaceutical Research Co., Ltd
Healthy
Phase 2B Study to Evaluate the Efficacy of Bentracimab (PB2452) in Reversal of Ticagrelor in Subjects Aged 50-80 Years Old
This phase 2B study is a multi-center, randomized, double-blind, placebo-controlled study. The study is designed to evaluate the efficacy of bentracimab (PB2452) in reversing the anti-platelet effects of ticagrelor as part of a…
- Trial name
- NCT04122170
- Testing
- Ticagrelor Oral Tablet - Pre-Treatment, Aspirin (ASA) Oral Tablet - Pre-Treatment, Bentracimab (PB2452) Infusion
- Where
- 15 sites in United States, Canada
- Volunteers
- 207 people, healthy volunteers welcome
- Sponsor
- SFJ Pharmaceuticals, Inc.
Myocardial Infarction, Myocardial Fibrosis
Modulation of Fibrosis-inducing Pathways in Acute Myocardial Infarction
This is a single-center, prospective, observational controlled cohort study designed to describe the role of WNT/B-catenin signaling and adenosine system after an acute myocardial infarction, correlating it with clinical markers…
- Conditions
- Myocardial Infarction, Myocardial Fibrosis, Myocardial Remodeling, Ventricular
- Trial name
- BETA-MI (NCT05122741)
- Testing
- P2Y12 Potent Inhibitor + Aspirin for STEMI patients, Clopidogrel + Aspirin for CCS patients
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- University of Messina
Coronary Artery Disease, Acute Coronary Syndrome
Ticagrelor Monotherapy in PAtients Treated With New-generation Drug-eluting Stents for Acute Coronary Syndrome; T-PASS Trial
We hypothesized that ticagrelor monotherapy might be enough to prevent thromboembolic events without aspirin after PCI in patients with acute coronary syndrome(ACS).
- Trial name
- NCT03797651
- Testing
- Standard DAPT, Very-short DAPT less than 1 month after PCI
- Where
- South Korea
- Volunteers
- 2,850 people
- Sponsor
- Yonsei University
Angina, Stable, Acute Coronary Syndrome
Genotyping GUided Antiplatelet theRapy in pAtieNts Treated With Drug Eluting stEnts (GUARANTEE)
The aim of this study is to assess the efficacy and safety of the CYP2C19 genotype guided antiplatelet treatment strategy, using clopidogrel in non-carriers of a CYP2C19*2 or *3 allele and ticagrelor in carriers of a CYP2C19*2 or…
- Conditions
- Angina, Stable, Acute Coronary Syndrome, Drug-Eluting Stents, Genotype
- Trial name
- NCT03783351
- Testing
- CYP2C19 genotype testing
- Where
- 9 sites in China
- Volunteers
- 4,009 people
- Sponsor
- Beijing Anzhen Hospital
Acute Myocardial Infarction, Ticagrelor
Optimal Dosage of Ticagrelor in Korean Patients With AMI
East Asian patients will be required optimal dose of newer P2Y12 inhibitor (ticagrelor) to determine the safer treatment and better outcome.
- Trial name
- NCT05210595
- Testing
- Clopidogrel 75 mg, Ticagrelor 60mg, Ticagrelor 45 mg
- Where
- South Korea
- Volunteers
- 120 people
- Sponsor
- Dong-A University
Acute Coronary Syndrome
ARCANGELO (itAlian pRospective Study on CANGrELOr)
The Sponsor implemented a post-authorisation safety study (PASS), category 3, focused in Acute Coronary Syndrome, in order to collect information about the safety of cangrelor in the real clinical practice, evaluating the safety…
- Trial name
- ARCANGELO (NCT04471870)
- Where
- 30 sites in Italy
- Volunteers
- 1,005 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Percutaneous Coronary Intervention
Fentanyl and Crushed Ticagrelor in Percutaneous Coronary Intervention
During a percutaneous coronary intervention (PCI), Fentanyl is commonly used for sedation. Ticagrelor is also routinely used as anti-platelet agent during PCI.
- Trial name
- FACTPCI (NCT03476369)
- Testing
- Fentanyl, Ticagrelor 90Mg Tablet
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- The Guthrie Clinic
Cardiovascular Diseases
In Vitro Interaction Between Ticagrelor and Its Active Metabolite and Their Effects on Salicylic Acid
This is a in-vitro study to evaluate the pharmacodynamic interaction between ticagrelor and its active metabolite (AR-C124910XX) and their effects on the pharmacodynamics of salicylic acid.
- Trial name
- In_vitro_PAT (NCT01777516)
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Asan Medical Center
Coronary Artery Disease
Reversal of the Anti-platelet Effects of Ticagrelor
The purpose of this study is to determine the proportion of untreated donor platelets required to fully reverse the platelet inhibitory effects of ticagrelor and aspirin in healthy persons and patients with coronary artery…
- Trial name
- REVERSAL (NCT02383771)
- Testing
- Ticagrelor, Aspirin + Ticagrelor, Control
- Where
- China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Severe Aortic Valve Stenosis, Aortic Valve Stenosis
Single Antiplatelet Treatment With Ticagrelor or Aspirin After Transcatheter Aortic Valve Implantation
The optimal pharmacological therapy after transcatheter aortic valve implantation (TAVI) to prevent valve thrombosis and reduce thromboembolic complications without significantly increasing the risk of bleeding is not yet fully…
- Conditions
- Severe Aortic Valve Stenosis, Aortic Valve Stenosis, Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Aortic Valve Implantation (TAVI)
- Trial name
- REAC-TAVI2 (NCT05283356)
- Testing
- Ticagrelor 60mg
- Where
- Spain
- Volunteers
- 1,206 people
- Sponsor
- Fundacin Biomedica Galicia Sur
Intracranial Aneurysm
A Multicenter Prospective Study of New Flow Diverter Stent on the Treatment of Intracranial Aneurysms in China
Intracranial aneurysm, as a common cerebrovascular disease, has a variety of treatment methods, including surgical treatment and endovascular treatment.
- Trial name
- APRESENT (NCT07821957)
- Testing
- Novel Flow Diverter Stent
- Where
- China
- Volunteers
- 280 people
- Sponsor
- Beijing Tiantan Hospital
Acute Coronary Syndrome
ADHerence of ticagrelOr in Real World Patients With aCute Coronary Syndrome
Ticagrelor 90 mg twice daily treatment is recommended for 12 months in patients with acute coronary syndrome (ACS) and in patients undergoing coronary revascularization and conservative strategies.
- Trial name
- AD-HOC (NCT03129867)
- Testing
- Ticagrelor
- Volunteers
- 480 people
- Sponsor
- FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Acute Coronary Syndrome, Percutaneous Coronary Intervention
Sequential MonotherApy of TicagrElor and Clopidogrel After Coronary Intervention
The MATE study is a randomized, multicenter, open-label, investigator-initiated clinical trial aimed to evaluate efficacy and safety of sequential monotherapy of ticagrelor and clopidogrel in patients with acute coronary syndrome…
- Trial name
- MATE (NCT04937699)
- Testing
- Standard-DAPT of Ticagrelor plus aspirin, Sequential monotherapy of Ticagrelor and clopidogrel
- Where
- China
- Volunteers
- 2,690 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Pharmacokinetics
An Open-Label, Single and Multiple Dose Pharmacokinetic Study of 90 mg and 180 mg Doses of AZD6140 in Healthy Volunteers
This will be a single centre study conducted at the 3rd hospital affiliated to Peking University. Approximately 24 healthy Chinese volunteers, male and female, will be recruited to obtain at least 20 evaluable volunteers.
- Trial name
- NCT00721448
- Testing
- AZD6140
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca